The controversial third phase of the German coalition government'shealth service reform has met opposition in the upper house of parliament.
The first of the third-phase revisions was rejected by a majority of the federal states controlled by the Social Democrats (SPD), and the second was referred to a joint committee for mediation. However, neither requires unanimity to succeed, and further stages can be carried in the lower house with the Chancellor's majority.
The first revision obliges health funds to link contribution rises to higher patient charges, a 0.1% increase putting 1 Deutschemark ($0.58) on charges. When fund premiums rise, members can switch relatively quickly. The second sets a 5-mark rise in patient contributions for drugs and other services, and global drug spending limits through pack size guidelines which, says the government, will give doctors more control over their spending.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze